Related Drugs: Entresto Sprinkle
Entresto (sacubitril/valsartan) is prescribed to reduce the risk of heart-related death and hospitalization for adults with heart failure. It is also used to treat heart failure symptoms in children who are at least one year old.
In general, the names and strengths of drugs can vary globally due to differing marketing strategies. This is the case with sacubitril/valsartan (brand names: Entresto, Vymada, CIDMUS, Oneptus, Azmarda, Neparvis, Sacurise). Any variations need to be approved by your prescriber.
Novartis markets sacubitril/valsartan under the name Entresto in the United States, UK, and Canada with the strengths 24/26 mg, 49/51 mg, and 97/103 mg.
Novartis markets sacubitril/valsartan in India and South Africa under the name Vymada with strengths 50mg, 100mg, and 200mg.
Dr. Reddy’s markets sacubitril/valsartan in India under the name CIDMUS with the strengths 50mg, 100mg, and 200mg. Cipla also markets sacubitril/valsartan under those same strengths in India. Sun Pharma markets it under the name Sacurise with those same strengths.
Novartis markets sacubitril/valsartan in Turkey under the name Oneptus with strengths of 24/26 mg, 49/51 mg, and 97/103 mg.
PharmacyChecker has also seen sacubitril/valsartan sold under the brand names Azmarda (in India) and Neparvis (in Europe).
As of July 2024, the FDA has approved a handful of generic versions for Entresto. However, these generics may not be available at U.S. pharmacies until the following year, when one of the Novartis patents expires in July 2025. Americans can save money on Entresto by comparing prices at international online pharmacies with discount prices available at U.S. pharmacies. Accredited international online pharmacies may carry alternative brand names.
Entresto sold in the U.S. is manufactured by Novartis in Singapore. Entresto Sprinkle sold in the U.S. is manufactured by Novartis in Slovenia.
Entresto (sacubitril/valsartan) is prescribed to reduce the risk of heart-related death and hospitalization for adults with heart failure. It is also used to treat heart failure symptoms in children who are at least one year old.
In general, the names and strengths of drugs can vary globally due to differing marketing strategies.
This is the case with sacubitril/valsartan (brand names: Entresto, Vymada, CIDMUS, Oneptus, Azmarda, Neparvis, Sacurise). Any variations need to be approved by your prescriber.
Novartis markets sacubitril/valsartan under the name Entresto in the United States, UK, and Canada with the strengths 24/26 mg, 49/51 mg, and 97/103 mg.
Novartis markets sacubitril/valsartan in India and South Africa under the name Vymada with strengths 50mg, 100mg, and 200mg.
Dr. Reddy’s markets sacubitril/valsartan in India under the name CIDMUS with the strengths 50mg, 100mg, and 200mg. Cipla also markets sacubitril/valsartan under those same strengths in India. Sun Pharma markets it under the name Sacurise with those same strengths.
Novartis markets sacubitril/valsartan in Turkey under the name Oneptus with strengths of 24/26 mg, 49/51 mg, and 97/103 mg.
PharmacyChecker has also seen sacubitril/valsartan sold under the brand names Azmarda (in India) and Neparvis (in Europe).
As of July 2024, the FDA has approved a handful of generic versions for Entresto. However, these generics may not be available at U.S. pharmacies until the following year, when one of the Novartis patents expires in July 2025. Americans can save money on Entresto by comparing prices at international online pharmacies with discount prices available at U.S. pharmacies. Accredited international online pharmacies may carry alternative brand names.
Entresto sold in the U.S. is manufactured by Novartis in Singapore. Entresto Sprinkle sold in the U.S. is manufactured by Novartis in Slovenia.